Skip to main content

Beardsley Robert A's Form 4 filing

Arbutus Biopharma Corp (ABUS) · filed Sep 23, 2026

Accession no.
0001447028-26-000050
Filed
Sep 23, 2026, 8:31 PM ET
Trade date
Sep 18, 2026
Filing delay
5 daysLate
Rule 10b5-1 plan
Not checked

This filing lists 3 non-derivative transactions and 2 derivative transactions. It was filed 5 days after the trade, past the 2-business-day deadline.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Beardsley Robert ACIK 0001310845Director

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Sep 18, 2026Common SharesMOption exerciseAcquired+52,533$3.20+$168,105.652,533Direct
Sep 18, 2026Common SharesMOption exerciseAcquired+78,800$4.24+$334,112131,333Direct
Sep 18, 2026Common SharesFTax withholdingDisposed−99,057$5.07−$502,218.9932,276Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Sep 18, 2026Common SharesMOption exerciseDisposed−52,533$0.00$0105,067Direct
Sep 18, 2026Common SharesMOption exerciseDisposed−78,800$0.00$00Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

No transaction price on this filing refers to a footnote.

Read the full filing on SEC EDGAR (opens in a new tab)